Stay updated on CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma

Sign up to get notified when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.
Latest website image capture
Clouds background image

Latest updates to the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The history now includes revision v3.4.3 and excludes v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-06T15:18:30.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    A new version entry on 2026-02-09 adds updates to Study Status and Contacts/Locations, with Revision: v3.4.2. The history also shows a prior deletion entry on 2025-11-12 (Revision: v3.4.1).
    Difference
    0.4%
    Check dated 2026-02-12T20:47:43.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision history now shows an addition of Revision: v3.4.1 and removal of Revision: v3.4.0, reflecting a minor version update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T12:21:08.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The changes introduce a glossary display and color-coded highlights for additions and deletions, with an updated revision label (v3.4.0). No FEAR Act data was removed.
    Difference
    0.7%
    Check dated 2026-01-29T06:36:52.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added to the page history and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T02:58:36.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Revision: v3.3.3 is now displayed in the footer, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 have been removed.
    Difference
    0.1%
    Check dated 2025-12-24T11:25:42.000Z thumbnail image

Stay in the know with updates to CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma

Enter your email address, and we'll notify you when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.